NMD_Logo3_reg.jpg
NMD Pharma to Present Data on its Skeletal Muscle Targeted Therapy for Rare Neuromuscular Diseases at the 2024 AANEM Annual Meeting
October 11, 2024 07:00 ET | NMD Pharma
NMD Pharma to Present Data on its Skeletal Muscle Targeted Therapy for Rare Neuromuscular Diseases at the 2024 AANEM Annual Meeting Aarhus, Denmark, 11 October 2024 – NMD Pharma A/S, a...
NMD_Logo3_reg.jpg
NMD Pharma to Present Data on its Skeletal Muscle Targeted Therapy for Rare Neuromuscular Diseases at the 2024 AANEM Annual Meeting
October 11, 2024 01:00 ET | NMD Pharma
NMD Pharma to Present Data on its Skeletal Muscle Targeted Therapy for Rare Neuromuscular Diseases at the 2024 AANEM Annual Meeting Aarhus, Denmark, 11 October 2024 – NMD Pharma A/S, a...
NMD_Logo3_reg.jpg
NMD Pharma adds new capabilities with several senior recruits to support its growing business and pipeline
July 11, 2024 07:00 ET | NMD Pharma
NMD Pharma adds new capabilities with several senior recruits to support its growing business and pipeline Aarhus, Denmark, 11 July 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated...
NMD_Logo3_reg.jpg
NMD Pharma adds new capabilities with several senior recruits to support its growing business and pipeline
July 11, 2024 01:00 ET | NMD Pharma
NMD Pharma adds new capabilities with several senior recruits to support its growing business and pipeline Aarhus, Denmark, 11 July 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated...
NMD_Logo3_reg.jpg
NMD Pharma Receives IND Clearance from the FDA to initiate a Phase 2 Clinical Trial of NMD670 in Charcot-Marie-Tooth disease in the US
June 18, 2024 07:00 ET | NMD Pharma
NMD Pharma Receives IND Clearance from the FDA to initiate a Phase 2 Clinical Trial of NMD670 in Charcot-Marie-Tooth disease in the US Aarhus, Denmark, 18 June 2024 – NMD Pharma A/S, a clinical-stage...
NMD_Logo3_reg.jpg
NMD Pharma Receives IND Clearance from the FDA to initiate a Phase 2 Clinical Trial of NMD670 in Charcot-Marie-Tooth disease in the US
June 18, 2024 01:00 ET | NMD Pharma
NMD Pharma Receives IND Clearance from the FDA to initiate a Phase 2 Clinical Trial of NMD670 in Charcot-Marie-Tooth disease in the US Aarhus, Denmark, 18 June 2024 – NMD Pharma A/S, a clinical-stage...
NMD_Logo3_reg.jpg
NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients
June 11, 2024 06:00 ET | NMD Pharma
NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients Aarhus, Denmark, 11 June 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel...
NMD_Logo3_reg.jpg
NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients
June 11, 2024 01:00 ET | NMD Pharma
NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients Aarhus, Denmark, 11 June 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated to developing...
NMD_Logo3_reg.jpg
NMD Pharma Receives FDA IND Clearance to initiate a Phase 2b Clinical Trial of NMD670 in Generalized Myasthenia Gravis Patients in the US
March 22, 2024 07:00 ET | NMD Pharma
NMD Pharma Receives FDA IND Clearance to initiate a Phase 2b Clinical Trial of NMD670 in Generalized Myasthenia Gravis Patients in the US Aarhus, Denmark, 22 March 2024 – NMD Pharma A/S, a...
NMD_Logo3_reg.jpg
NMD Pharma Receives FDA IND Clearance to initiate a Phase 2b Clinical Trial of NMD670 in Generalized Myasthenia Gravis Patients in the US
March 22, 2024 02:00 ET | NMD Pharma
NMD Pharma Receives FDA IND Clearance to initiate a Phase 2b Clinical Trial of NMD670 in Generalized Myasthenia Gravis Patients in the US Aarhus, Denmark, 22 March 2024 – NMD Pharma A/S, a...